Backbone and benzoyl mustard carrying moiety modifies DNA interactions of distamycin analogues

被引:14
作者
Ciucci, A
Manzini, S
Lombardi, P
Arcamone, F
机构
[1] Menarini Ricerche Sud, 00040 Pomezia, Rome
关键词
D O I
10.1093/nar/24.2.311
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Alkylating distamycin derivative FCE 24517 (I) is the prototype of a novel class of alkylating agents, In the present study we have investigated the effect of further chemical modifications introduced in the alkylating distamycin-derived molecule with the aim of improving their ability to bind DNA, The new compound, MEN 10710 (II), has a four pyrrolecarboxamide backbone linked at its N-terminus and through a butanamido residue to a 4-[bis(2-chloroethyl)amino]phenyl moiety. We have demonstrated that the presence of the flexible trimethylene chain confers to the novel distamycin derivative a peculiar mode of interaction with DNA as compared with I or melphalan. In fact, interstrand cross-links are detected in DNA samples treated even with low concentrations of II (being 200-fold more efficient than melphalan) but not with I. Similar results were obtained with a related compound of II containing a three pyrrole ring backbone. Compound II induces a conformational change in the DNA structure as deduced from the inhibition of T4 DNA ligase activity. In alkylation experiments, unlike melphalan, both I and II induce DNA breaks at bases closely located to AT-rich tracts, however II was more potent than I in producing greater amount of covalent adducts. These data suggest that the new compound shows a different and peculiar mechanism of interaction with DNA.
引用
收藏
页码:311 / 315
页数:5
相关论文
共 22 条
[1]   SYNTHESIS OF 2 DISTAMYCIN ANALOGS AND THEIR BINDING MODE TO D(CGCAAATTTGCG)(2) IN THE 2/1 SOLUTION COMPLEXES AS DETERMINED BY 2-DIMENSIONAL H-1-NMR [J].
ANIMATI, F ;
ARCAMONE, FM ;
CONTE, MR ;
FELICETTI, P ;
GALEONE, A ;
LOMBARDI, P ;
MAYOL, L ;
PALOMA, LG ;
ROSSI, C .
JOURNAL OF MEDICINAL CHEMISTRY, 1995, 38 (07) :1140-1149
[2]   SYNTHESIS, DNA-BINDING PROPERTIES, AND ANTITUMOR-ACTIVITY OF NOVEL DISTAMYCIN DERIVATIVES [J].
ARCAMONE, FM ;
ANIMATI, F ;
BARBIERI, B ;
CONFIGLIACCHI, E ;
DALESSIO, R ;
GERONI, C ;
GIULIANI, FC ;
LAZZARI, E ;
MENOZZI, M ;
MONGELLI, N ;
PENCO, S ;
VERINI, MA .
JOURNAL OF MEDICINAL CHEMISTRY, 1989, 32 (04) :774-778
[3]  
BARBIERI B, 1988, P AM ASSOC CANC RES, V29, P330
[4]  
Bigioni M., 1995, Proceedings of the American Association for Cancer Research Annual Meeting, V36, P375
[5]  
BROGGINI M, 1991, CANCER RES, V51, P199
[6]   DISTAMYCIN ANALOGS WITH IMPROVED SEQUENCE-SPECIFIC DNA-BINDING ACTIVITIES [J].
CIUCCI, A ;
FERIOTTO, G ;
MISCHIATI, C ;
GAMBARI, R ;
ANIMATI, F ;
LOMBARDI, P ;
NATALI, PG ;
ARCAMONE, F ;
GIACOMINI, P .
BIOCHEMICAL PHARMACOLOGY, 1994, 48 (08) :1583-1591
[7]   BINDING OF EPSTEIN-BARR-VIRUS NUCLEAR ANTIGEN-1 TO DNA - INHIBITION BY DISTAMYCIN AND 2 NOVEL DISTAMYCIN ANALOGS [J].
FERIOTTO, G ;
CIUCCI, A ;
MISCHIATI, C ;
ANIMATI, F ;
LOMBARDI, P ;
GIACOMINI, P ;
ARCAMONE, F ;
GAMBARI, R .
EUROPEAN JOURNAL OF PHARMACOLOGY-MOLECULAR PHARMACOLOGY SECTION, 1994, 267 (02) :143-149
[8]  
FONTANA M, 1992, ANTI-CANCER DRUG DES, V7, P131
[9]  
GIULIANI FC, 1988, P AM ASSOC CANC RES, V29, P330
[10]  
HARTLEY JA, 1986, CANCER RES, V46, P1943